多西他赛辅助治疗淋巴结阳性乳腺癌。 - Suppr | 超能文献

Adjuvant docetaxel for node-positive breast cancer.

作者信息

Ahluwalia Manmeet S, Daw Hamed A

出版信息

N Engl J Med. 2005 Sep 1;353(9):954-5; author reply 954-5. doi: 10.1056/NEJMc051802.

DOI:10.1056/NEJMc051802

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Adjuvant docetaxel for node-positive breast cancer.

N Engl J Med. 2005 Sep 1;353(9):954-5; author reply 954-5. doi: 10.1056/NEJMc051802.

2

Adjuvant docetaxel for node-positive breast cancer.

N Engl J Med. 2005 Sep 1;353(9):954-5; author reply 954-5.

3

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

Ann Oncol. 2016 Jun;27(6):1041-1047. doi: 10.1093/annonc/mdw098. Epub 2016 Mar 2.

4

Adjuvant docetaxel for node-positive breast cancer.

N Engl J Med. 2005 Jun 2;352(22):2302-13. doi: 10.1056/NEJMoa043681.

5

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

Ann Oncol. 2006 Aug;17(8):1205-12. doi: 10.1093/annonc/mdl135. Epub 2006 Jun 9.

6

Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC).

Pathol Oncol Res. 2003;9(3):166-9. doi: 10.1007/BF03033731. Epub 2003 Oct 7.

7

Anthracycline-based adjuvant chemotherapy in breast cancer.

Lancet. 2010 May 29;375(9729):1871; author reply 1871-2. doi: 10.1016/S0140-6736(10)60868-9.

8

Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.

J Clin Oncol. 2008 Feb 20;26(6):925-33. doi: 10.1200/JCO.2006.10.4190.

9

Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.

Clin Breast Cancer. 2007 Aug;7(9):697-704. doi: 10.3816/CBC.2007.n.029.

10

Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer.

Ann Oncol. 2005 Feb;16(2):247-52. doi: 10.1093/annonc/mdi058.

引用本文的文献

1

M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling.

Onco Targets Ther. 2019 Apr 18;12:3051-3063. doi: 10.2147/OTT.S198126. eCollection 2019.